Edition:
India

Novo Nordisk A/S (NVO.N)

NVO.N on New York Stock Exchange

43.85USD
1:32am IST
Change (% chg)

$-0.58 (-1.31%)
Prev Close
$44.43
Open
$43.70
Day's High
$43.93
Day's Low
$43.35
Volume
702,477
Avg. Vol
375,977
52-wk High
$58.99
52-wk Low
$43.35

NVO.N

Chart for NVO.N

About

Novo Nordisk A/S is a healthcare company. The Company is engaged in discovery, development, manufacturing and marketing of pharmaceutical products. The Company's business segments include diabetes and obesity care, and biopharmaceuticals. The diabetes and obesity care segment covers insulins, glucagon-like peptide-1 (GLP-1),... (more)

Overall

Beta: 0.72
Market Cap(Mil.): $89,770.57
Shares Outstanding(Mil.): 2,012.56
Dividend: 0.45
Yield (%): 2.04

Financials

  NVO.N Industry Sector
P/E (TTM): 20.82 36.26 36.23
EPS (TTM): 2.13 -- --
ROI: 80.63 14.29 13.79
ROE: 88.29 15.13 14.74

BRIEF-Novo submits label application in the US for insulin drug Tresiba

* Says has submitted a supplemental application to the US Food and Drug Administration (FDA) for including results from its two SWITCH trials in insulin drug Tresiba's label

23 Sep 2016

UPDATE 1-Novo Nordisk to supply insulin at discount to poorest nations

NEW YORK, Sept 21 Danish drugmaker Novo Nordisk A/S pledged on Wednesday to provide insulin at steeply discounted prices in the world's least-developed nations in what it is calling its "access to insulin commitment."

22 Sep 2016

Novo Nordisk to supply insulin at discount to poorest nations

NEW YORK, Sept 21 Danish drugmaker Novo Nordisk A/S on Wednesday pledged to provide insulin at steeply discounted prices in the world's least-developed nations in what it is calling its "access to insulin commitment."

21 Sep 2016

Novo plans larger study after encouraging semaglutide results

COPENHAGEN Novo Nordisk's experimental injectable diabetes drug semaglutide reduced cardiovascular risk by 26 percent, according to results released on Friday, paving the way for a new and bigger study on the drug's benefits.

16 Sep 2016

UPDATE 1-Novo Nordisk's diabetes drug semaglutide cuts heart risk by 26 percent

COPENHAGEN, Sept 16 Novo Nordisk's experimental injectable diabetes drug semaglutide reduced cardiovascular risk by 26 percent according to the keenly awaited results of a clinical trial released on Friday.

16 Sep 2016

Novo Nordisk says diabetes drug semaglutide cuts heart risk by 26 percent

COPENHAGEN, Sept 16 Novo Nordisk's experimental injectable diabetes drug semaglutide reduced cardiovascular risk by 26 percent in a keenly awaited clinical, according to results released on Friday.

16 Sep 2016

European shares slip as healthcare stocks lose ground

LONDON, Sept 9 European stock markets fell on Friday, weighed down by a drop in the shares of healthcare companies, while the latest nuclear test conducted by North Korea also rattled markets.

09 Sep 2016

Novo Nordisk's veteran CEO Lars Rebien Sorensen to step down

COPENHAGEN Novo Nordisk's long-serving chief executive Lars Rebien Sorensen is to step down early, it was announced on Thursday, at a time when the world's largest insulin maker has said it faces increased competition in the U.S. market where it generates about half its revenues.

01 Sep 2016

UPDATE 3-Novo Nordisk's veteran CEO Lars Rebien Sorensen to step down

* Move is acknowledgement of serious U.S. challenges - analyst (Adds comments by CEO, chairman)

01 Sep 2016

BRIEF-Novo Nordisk CEO questions if company has the right R&D strategy

Sept 1 Chief Executive Lars Rebien Sorensen, Novo Nordisk A/S :

01 Sep 2016

Competitors

  Price Chg
Sanofi SA (SASY.PA) €67.94 --
Eli Lilly and Co (LLY.N) $80.88 +1.36

Earnings vs. Estimates